<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DOXERCALCIFEROL- doxercalciferol capsule </strong><br>Roxane Laboratories, Inc.<br></p></div>
<h1><span class="Bold">DOXERCALCIFEROL Capsules</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d999df74-8040-4913-b869-c996d4028a5a"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5c6d22a5-fe35-42ce-8a24-a5fa2047daff"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Doxercalciferol, the active ingredient in Doxercalciferol Capsules, is a synthetic vitamin D<span class="Sub">2</span> analog that undergoes metabolic activation <span class="Italics">in vivo </span>to form 1α,25-dihydroxyvitamin D<span class="Sub">2</span> (1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span>), a naturally occurring, biologically active form of vitamin D<span class="Sub">2</span>. Doxercalciferol Capsules are available as a soft gelatin capsule containing 0.5 mcg or 2.5 mcg doxercalciferol. Each capsule also contains butylated hydroxyanisole (BHA), dehydrated alcohol, and medium chain triglyceride. The capsule shells contain D&amp;C Yellow No. 10 (0.5 mcg and 2.5 mcg), FD&amp;C Yellow No. 6 (1 mcg only), FD&amp;C Red No. 40 (0.5 mcg only), gelatin, glycerin, Opacode Black, purified water, and titanium dioxide. Opacode Black contains ammonium hydroxide, iron oxide black, isopropyl alcohol, N-butyl alcohol, propylene glycol, and shellac.</p>
<p>Doxercalciferol is a colorless crystalline compound with a calculated molecular weight of 412.66 and a molecular formula of C<span class="Sub">28</span>H<span class="Sub">44</span>O<span class="Sub">2</span>. It is soluble in oils and organic solvents, but is relatively insoluble in water. Chemically, doxercalciferol is (1α,3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol and has the following structural formula:</p>
<div class="Figure">
<a name="id423"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Doxercalciferol Capsules SPL\Labels\Doxercalciferol Capsules Chem Struc.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed&amp;name=1bb3ce2f-c77a-436f-980f-a02668f99fed-01.jpg">
</div>
<p>Other names frequently used for doxercalciferol are 1α-hydroxyvitamin D<span class="Sub">2</span>, 1α-OH-D<span class="Sub">2</span>, and 1α-hydroxyergocalciferol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_71f42e37-bff7-4d20-b618-e69a41de2502"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Vitamin D levels in humans depend on two sources: (1) exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D<span class="Sub">3</span> (cholecalciferol) and (2) dietary intake of either vitamin D<span class="Sub">2</span> (ergocalciferol) or vitamin D<span class="Sub">3</span>. Vitamin D<span class="Sub">2</span> and vitamin D<span class="Sub">3</span> must be metabolically activated in the liver and the kidney before becoming fully active on target tissues. The initial step in the activation process is the introduction of a hydroxyl group in the side chain at C-25 by the hepatic enzyme, CYP 27 (α vitamin D-25-hydroxylase). The products of this reaction are 25-(OH)D<span class="Sub">2</span> and 25-(OH)D<span class="Sub">3</span>, respectively. Further hydroxylation of these metabolites occurs in the mitochondria of kidney tissue, catalyzed by renal 25-hydroxyvitamin D-1-α-hydroxylase to produce 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span>, the primary biologically active form of vitamin D<span class="Sub">2</span>, and 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">3</span> (calcitriol), the biologically active form of vitamin D<span class="Sub">3</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5f05cee-b6ea-4a9b-a790-137f065600e0"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Calcitriol (1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">3</span>) and 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span> regulate blood calcium at levels required for essential body functions. Specifically, the biologically active vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. These functions are mediated by the interaction of these biologically active metabolites with specific receptor proteins in the various target tissues. In patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD), deficient production of biologically active vitamin D metabolites (due to lack of or insufficient 25-hydroxyvitamin D-1-alpha-hydroxylase activity) leads to secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>, which contributes to the development of metabolic bone disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b6f1af2-eade-49e4-9142-102ac866c135"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">Doxercalciferol is absorbed from the gastrointestinal tract and activated by CYP 27 in the liver to form 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span> (major metabolite) and 1α,24-dihydroxyvitamin D<span class="Sub">2</span> (minor metabolite). Activation of doxercalciferol does not require the involvement of the kidneys. </p>
<p>In healthy volunteers, peak blood levels of 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span>, the major metabolite of doxercalciferol, are attained at 11 to 12 hours after repeated oral doses of 5 to 15 mcg of doxercalciferol and the mean elimination half-life of 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span> is approximately 32 to 37 hours with a range of up to 96 hours. The mean elimination half-life in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) on dialysis appears to be similar. Hemodialysis causes a temporary increase in 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span> mean concentrations, presumably due to volume contraction. 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span> is not removed from blood during hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b51e3543-f8b5-4d5d-a2aa-a911f4a95b1a"></a><a name="section-3.3"></a><p></p>
<h2>Clinical Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fed61ebb-dea4-4dc6-88d4-a61a72cbde5d"></a><a name="section-3.3.1"></a><p></p>
<h3>Dialysis</h3>
<p class="First">The safety and effectiveness of doxercalciferol was evaluated in two double-blind, placebo-controlled, multicentered clinical studies (Study A and Study B) in a total of 138 patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on hemodialysis (Stage 5 CKD). Patients in Study A were an average age of 52 years (range: 22 to 75), were 55% male, and were 58% African-American, 31% Caucasian, and 11% Hispanic, and had been on hemodialysis for an average of 53 months. Patients in Study B were an average of 52 years (range: 27 to 75), were 45% male, and 99% African-American, and 1% Caucasian, and had been on hemodialysis for an average of 56 months. After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, all patients received doxercalciferol in an open-label fashion for 16 weeks followed by a double-blind period of 8 weeks during which patients received either doxercalciferol or placebo. The initial dose of doxercalciferol during the open-label phase was 10 micrograms after each dialysis session (3 times weekly) for a total of 30 mcg per week. The dosage of doxercalciferol was adjusted as necessary by the investigator in an attempt to achieve intact parathyroid hormone (iPTH) levels within a targeted range of 150 to 300 pg/mL. The maximum dosage was limited to 20 mcg after each dialysis session (60 mcg/week). If at any time during the trial iPTH fell below 150 pg/mL, doxercalciferol was immediately suspended and restarted at a lower dosage the following week.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41a24646-d6d7-49c5-8d42-e6308802b35f"></a><a name="section-3.3.2"></a><p></p>
<h3>Results</h3>
<p class="First">One hundred and six of the 138 patients who were treated with doxercalciferol during the 16-week open-label phase achieved iPTH levels ≤300 pg/mL. Ninety-four of these patients exhibited plasma iPTH levels ≤300 pg/mL on at least 3 occasions. Eighty-seven patients had plasma iPTH levels &lt;150 pg/mL on at least one occasion during the open-label phase of study participation.</p>
<p>Mean weekly doses during the 16-week open-label period in Study A ranged from 14.8 mcg to 28.7 mcg. In Study B, the mean weekly doses during the 16-week open-label period ranged from 19.2 mcg to 28 mcg.</p>
<p>Decreases in plasma iPTH from baseline values were calculated using as baseline the average of the last 3 values obtained during the 8-week washout phase and are displayed in <span class="Bold">Table 1</span> below.</p>
<a name="_Refid_2120ccba-43d1-4114-bc07-a78d3a389"></a><table>
<caption><span>Table 1: iPTH Summary Data for Dialysis Patients Receiving Doxercalciferol</span></caption>
<col width="13%">
<col width="20%">
<col width="33%">
<col width="34%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>all subjects; last value carried to discontinuation</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" colspan="2" rowspan="4"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">iPTH (pg/mL)</span></p></td>
</tr>
<tr><td class="Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">means ± s.d. (n</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Bold">)</span></p></td></tr>
<tr><td class="Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">p Value <span class="Italics">v.</span> Baseline</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">p Value <span class="Italics">v.</span> Placebo</span></p></td></tr>
<tr>
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Doxercalciferol</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Study A</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Baseline</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">797.2 ± 443.8 (30)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">847.1 ± 765.5 (32)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">n.a.</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.97</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Week 16 </p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">384.3 ± 397.8 (24)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">526.5 ± 872.2 (29)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">(open-label)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.72</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Week 24</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">404.4 ± 262.9 (21)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">672.6 ± 356.9 (24)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">(double-blind)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
<td class="Lrule Rrule" align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.008</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Study B</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Baseline</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">973.9 ± 567 (41)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">990.4 ± 488.3 (35)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">n.a.</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.81</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Week 16</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">476.1 ± 444.5 (37)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">485.9 ± 443.4 (32)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">(open-label)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.91</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Week 24</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">459.8 ± 443 (35)</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">871.9 ± 623.6 (30)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">(double-blind)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;0.065</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;0.001</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
<p>In both studies, iPTH levels increased progressively and significantly in 65.9% of the patients during the 8-week washout (control) period during which no vitamin D derivatives were administered. In contrast, doxercalciferol treatment resulted in a statistically significant reduction from baseline in mean iPTH levels during the 16-week open-label treatment period in more than 93.5% of the 138 treated patients. During the double-blind period (weeks 17 to 24), the reduction in mean iPTH levels was maintained in the doxercalciferol treatment group compared to a return to near baseline in the placebo group.</p>
<p>In the clinical trials, the values for iPTH varied widely from patient to patient and from week to week for individual patients. <span class="Bold">Table 2</span> shows the numbers of patients within each group who achieved and maintained iPTH levels below 300 pg/mL during the open-label and double-blind phases. Seventy-four of 138 patients (53.6%) had plasma iPTH levels within the target range (150 to 300 pg/mL) during Weeks 14 to 16.</p>
<a name="_Refid_ddf75e78-dcb3-401a-9880-fe19e9390"></a><table>
<caption><span>Table 2: Number of Times iPTH ≤300 pg/mL</span></caption>
<col width="8%">
<col width="12%">
<col width="17%">
<col width="10%">
<col width="17%">
<col width="10%">
<col width="17%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">1</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">2</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">≥3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">Doxercalciferol</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Doxercalciferol</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Doxercalciferol</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Placebo</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Study A</p></td>
<td class="Rrule"><p class="First">Weeks 1-16</p></td>
<td class="Rrule" align="center"><p class="First">2/30</p></td>
<td class="Rrule" align="center"><p class="First">2/32</p></td>
<td class="Rrule" align="center"><p class="First">0/30</p></td>
<td class="Rrule" align="center"><p class="First">0/32</p></td>
<td class="Rrule" align="center"><p class="First">22/30</p></td>
<td class="Rrule" align="center"><p class="First">23/32</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First">(open-label)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Rrule"><p class="First">Weeks 17-24</p></td>
<td class="Rrule" align="center"><p class="First">0/24</p></td>
<td class="Rrule" align="center"><p class="First">9/29</p></td>
<td class="Rrule" align="center"><p class="First">3/24</p></td>
<td class="Rrule" align="center"><p class="First">1/29</p></td>
<td class="Rrule" align="center"><p class="First">17/24</p></td>
<td class="Rrule" align="center"><p class="First">5/29</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First">(double-blind)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Study B</p></td>
<td class="Rrule"><p class="First">Weeks 1-16</p></td>
<td class="Rrule" align="center"><p class="First">2/41</p></td>
<td class="Rrule" align="center"><p class="First">4/35</p></td>
<td class="Rrule" align="center"><p class="First">1/41</p></td>
<td class="Rrule" align="center"><p class="First">0/35</p></td>
<td class="Rrule" align="center"><p class="First">29/41</p></td>
<td class="Rrule" align="center"><p class="First">21/35</p></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First">(open-label)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Rrule"><p class="First">Weeks 17-24</p></td>
<td class="Rrule" align="center"><p class="First">2/37</p></td>
<td class="Rrule" align="center"><p class="First">6/32</p></td>
<td class="Rrule" align="center"><p class="First">1/37</p></td>
<td class="Rrule" align="center"><p class="First">4/32</p></td>
<td class="Rrule" align="center"><p class="First">26/37</p></td>
<td class="Rrule" align="center"><p class="First">4/32</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First">(double-blind)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
</tbody>
</table>
<p>During the 8-week double-blind phase, more patients achieved and maintained the target range of values for iPTH with doxercalciferol than with placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf115ac1-3a36-4fc0-a9af-219db33e7103"></a><a name="section-3.3.3"></a><p></p>
<h3>Pre-Dialysis</h3>
<p class="First">The safety and effectiveness of doxercalciferol were evaluated in two clinical studies in 55 patients with Stage 3 or Stage 4 <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>. Eighty-two percent of the patients were male, the average age was 64.6 years, 51% were Caucasian, 40% African-American, and the average serum iPTH level at baseline was 194.6 pg/mL. While levels of 25-(OH) vitamin D were not evaluated at baseline, retrospective assessments of stored serum revealed that the mean ±SD serum 25-(OH) vitamin D was 18.5 ± 8.1 ng/mL (range: &lt;5 to 54 ng/mL) in the study population.</p>
<p>After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, one group received doxercalciferol and the other placebo during a double-blind period of 24 weeks. The initial dose of doxercalciferol was 1 mcg per day. The dosage of doxercalciferol was adjusted as necessary by the investigator in order to reduce intact parathyroid hormone (iPTH) levels to a target of ≥30% below post-washout baseline. The maximum dosage was limited to 3.5 mcg per day. If at any time during the trial iPTH fell below 15 pg/mL, doxercalciferol was immediately suspended and restarted at a lower dosage the following week.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8cf6337-3856-4a44-ba14-c84a45130217"></a><a name="section-3.3.4"></a><p></p>
<h3>Results</h3>
<p class="First">Decreases in the mean plasma iPTH from baseline values were calculated using as baseline the average of the last 2 values obtained during the 8-week washout phase. In analyses of pooled data from the two studies, iPTH levels decreased from baseline by an average of 101.4 pg/mL in the doxercalciferol group and by 4.4 pg/mL in the placebo group (p&lt;0.001). Greater reductions of iPTH with doxercalciferol compared to placebo were observed in each study. Twenty (74%) of 27 subjects in the doxercalciferol group achieved mean plasma iPTH suppression of ≥30% from baseline for the last four weeks of treatment, whereas two (7%) of the 28 subjects treated with placebo achieved this level of iPTH suppression. In the doxercalciferol-treated patients, the reductions in plasma iPTH were associated with a reduction in serum bone-specific alkaline phosphatase.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_80e2ebf5-e1ae-4afb-aa3c-11085ad46e91"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b06c223-9064-47c1-a254-c44d3044605e"></a><a name="section-4.1"></a><p></p>
<h2>Dialysis Patients</h2>
<p class="First">Doxercalciferol Capsules are indicated for the treatment of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91623d02-fbbb-4865-a3f5-fd8c4ddc8788"></a><a name="section-4.2"></a><p></p>
<h2>Pre-Dialysis Patients</h2>
<p class="First">Doxercalciferol Capsules are indicated for the treatment of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in patients with Stage 3 or Stage 4 <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f0aaf582-4458-404f-a1fa-72661df1e2a3"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Doxercalciferol Capsules should not be given to patients with a tendency towards <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or current evidence of vitamin D toxicity.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_641554ee-601d-4b9a-ad45-814a514d0a29"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Overdosage of any form of vitamin D, including doxercalciferol, is dangerous (see <a href="#i4i_overdosage_id_885ace47-c251-4023-83b0-55747d2ffd2b">OVERDOSAGE</a>). Progressive <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to overdosage of vitamin D and its metabolites may be so severe as to require emergency attention. Acute <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may exacerbate tendencies for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and may potentiate the action of digitalis drugs. Chronic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> can lead to generalized <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span> and other soft-tissue calcification. The serum calcium times serum phosphorus (Ca X P) product should be maintained at &lt;55 mg<span class="Sup">2</span>/dL<span class="Sup">2</span> in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>. Radiographic evaluation of suspect anatomical regions may be useful in the early detection of this condition.</p>
<p>Since doxercalciferol is a precursor for 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span>, a potent metabolite of vitamin D<span class="Sub">2</span>, pharmacologic doses of vitamin D and its derivatives should be withheld during doxercalciferol treatment to avoid possible additive effects and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<p>Oral calcium-based or other non-aluminum-containing phosphate binders and a low phosphate diet should be used to control serum phosphorus levels in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>. Uncontrolled serum phosphorus exacerbates secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> and can lessen the effectiveness of doxercalciferol in reducing blood PTH levels. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs after initiating doxercalciferol therapy, the dose of doxercalciferol and/or calcium-containing phosphate binders should be decreased. If <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> occurs after initiating doxercalciferol therapy, the dose of doxercalciferol should be decreased and/or the dose of phosphate binders increased. (See dosing recommendations for doxercalciferol under <a href="#i4i_dosage_admin_id_1ede2c7f-0d1a-46ed-8348-2105dd3df30a">DOSAGE AND ADMINISTRATION</a> section.)</p>
<p>Magnesium-containing antacids and doxercalciferol should not be used concomitantly in patients on chronic renal dialysis because such use may lead to the development of <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d0788bb2-eb15-4f8f-ab89-9de0fd1b2d2b"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_03f887cc-981b-4aca-b067-f228e1988425"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Active vitamin D sterols should not be used as initial treatment of nutritional <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span> (as defined by low 25-hydroxy vitamin D). Patients should be checked and treated for nutritional <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span> prior to initiating treatment with doxercalciferol.</p>
<p>The principal adverse effects of treatment with doxercalciferol are <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, and oversuppression of PTH (iPTH less than 150 pg/mL). Prolonged <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> can lead to calcification of soft tissues, including the heart and arteries, and <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> can exacerbate <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">Hypercalciuria</span> can accelerate the onset of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> through <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>. Oversuppression of PTH may lead to adynamic bone syndrome. All of these potential adverse effects should be managed by regular patient monitoring and appropriate dosage adjustments. During treatment with doxercalciferol, patients usually require dose titration, as well as adjustment in co-therapy (i.e., dietary phosphate binders) in order to maximize PTH suppression while maintaining serum calcium and phosphorus within prescribed ranges.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c24a324e-2139-4c0d-9e47-c51b12107f35"></a><a name="section-7.1.1"></a><p></p>
<h3>Dialysis </h3>
<p class="First">In four adequate and well-controlled studies, the incidence of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> increased during therapy with doxercalciferol. The observed increases during doxercalciferol treatment, although occurring at a low rate, underscore the importance of regular safety monitoring of serum calcium and phosphorus levels throughout treatment. Patients with higher pre-treatment serum levels of calcium (&gt;10.5 mg/dL) or phosphorus (&gt;6.9 mg/dL) were more likely to experience <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. Therefore, doxercalciferol should not be given to patients with a recent history of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> or <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, or evidence of vitamin D toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa4e362c-0d0c-4dbd-aaaa-e685395d6065"></a><a name="section-7.1.2"></a><p></p>
<h3>Pre-Dialysis </h3>
<p class="First">In two clinical studies, the incidences of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> during therapy with doxercalciferol were similar to placebo therapy, and no episodes of <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> were observed. The baseline median 25-(OH) vitamin D levels of patients enrolled in these studies was 17.2 ng/mL. Ninety-three percent of patients had 25-(OH) vitamin D levels less than 30 ng/mL; 26% had 25-(OH) vitamin D levels ≥20 to &lt;30 ng/mL; 58% had levels &gt;10 to &lt;20 ng/mL; 7% had levels &gt;5 to &lt;10 ng/mL; and 2% had levels &lt;5 ng/mL. The incidences of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> in patients treated with doxercalciferol for <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> related to pre-dialysis <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> has not been fully studied when 25-OH vitamin D levels are greater than or equal to 30 ng/mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_954379d6-55fa-4a1a-8031-b46dc1364e0e"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The patient, spouse, or guardian should be informed about compliance with dosage instructions, adherence to instructions about diet, calcium supplementation, and avoidance of the use of nonprescription drugs without prior approval from their physician. Patients should also be carefully informed about the symptoms of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (see <span class="Bold"><a href="#i4i_adverse_effects_id_181bb0ea-2b57-4380-9fe5-879941086ccd">ADVERSE REACTIONS</a></span>section).</p>
<p>Patients' total combined elemental calcium intake (dietary and phosphate binder) should not exceed 2 g daily.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_6ecd3d8f-3ef5-42f8-a860-ef617742b7ee"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum or plasma iPTH and serum calcium, phosphorus, and alkaline phosphatase should be determined periodically. In the early phase of treatment for dialysis patients, iPTH, serum calcium, and serum phosphorus should be determined prior to initiation of doxercalciferol treatment and weekly thereafter. For pre-dialysis patients, serum levels of calcium and phosphorus and plasma levels of iPTH should be monitored at least every two weeks for 3 months after initiation of doxercalciferol therapy or following dose-adjustments in doxercalciferol therapy, then monthly for 3 months, and every 3 months thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c15e070e-fa5f-4446-90f8-68a9058b4f4f"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Specific drug interaction studies have not been conducted. Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; therefore, it may impair intestinal absorption of doxercalciferol. Magnesium-containing antacids and doxercalciferol should not be used concomitantly because such use may lead to the development of <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span> (see <span class="Bold"><a href="#i4i_warnings_id_641554ee-601d-4b9a-ad45-814a514d0a29">WARNINGS</a></span>). The use of mineral oil or other substances that may affect absorption of fat may influence the absorption and availability of doxercalciferol. Although not examined specifically, enzyme inducers (such as glutethimide and phenobarbital) may affect the 25-hydroxylation of doxercalciferol and may necessitate dosage adjustments. Cytochrome P450 inhibitors (such as ketoconazole and erythromycin) may inhibit the 25-hydroxylation of doxercalciferol. Hence, formation of the active doxercalciferol moiety may be hindered.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_5345929a-5d52-4025-a1d5-5e67a88d9476"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week carcinogenicity study in rats, there was an increased incidence of benign and malignant adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in both males and females at oral doses of 0.04, 0.13 and 0.39 mcg/kg/day (≤1 times the human exposure in pre-dialysis patients with a maximum recommended dose of 3.5 mcg/day or 24.5 mcg/week). This increased incidence of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in rats may be due to altered calcium homeostasis by doxercalciferol. No evidence of genetic toxicity was observed in an <span class="Italics">in vitro</span> bacterial mutagenicity assay (Ames test) or a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> gene mutation assay. Doxercalciferol caused structural chromatid and chromosome aberrations in an <span class="Italics">in vitro</span> human lymphocyte clastogenicity assay with metabolic activation. However, doxercalciferol was negative in an <span class="Italics">in vivo </span>mouse micronucleus clastogenicity assay. Doxercalciferol had no effect on male or female fertility in rats at oral doses up to 2.5 mcg/kg/day (approximately 3 times the maximum recommended human dose of 60 mcg/week based on mcg/m<span class="Sup">2</span> body surface area).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_a8790662-ecbf-4212-996b-eee829b0ebdc"></a><a name="section-7.6"></a><p></p>
<h2>Use in Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3538232-ea6d-4f59-a8d4-61136a3ec979"></a><a name="section-7.6.1"></a><p></p>
<h3>Pregnancy Category B</h3>
<p class="First">Reproduction studies in rats and rabbits, at doses up to 20 mcg/kg/day and 0.1 mcg/kg/day (approximately 25 times and less than the maximum recommended human dose of 60 mcg/week based on mcg/m<span class="Sup">2</span> body surface area, respectively) have revealed no teratogenic or fetotoxic effects due to doxercalciferol. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_b6d2b967-ab76-431d-8673-b2e22555c97e"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether doxercalciferol is excreted in human milk. Because other vitamin D derivatives are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from doxercalciferol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_4fd42ed4-5def-4921-bee7-a1b6b6ce37e6"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy of doxercalciferol in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_e27e9620-2b7a-4311-b5f6-846d2e2d4f4c"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 138 patients treated with doxercalciferol capsules in two Phase 3 clinical studies, 30 patients were 65 years or over. In these studies, no overall differences in efficacy or safety were observed between patients 65 years or older and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c34c019-b306-4560-9f63-e071fdc8e193"></a><a name="section-7.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Since patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> may not metabolize doxercalciferol appropriately, the drug should be used with caution in patients with impaired hepatic function. More frequent monitoring of iPTH, calcium, and phosphorus levels should be done in such individuals.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_181bb0ea-2b57-4380-9fe5-879941086ccd"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76a0c52e-ecf2-4a78-bb56-d8396ab2166a"></a><a name="section-8.1"></a><p></p>
<h2>Dialysis</h2>
<p class="First">Doxercalciferol has been evaluated for safety in clinical studies in 165 patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on hemodialysis. In two placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in 2.9% of 138 patients treated with doxercalciferol for four to six months (dosage titrated to achieve target iPTH levels, see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_71f42e37-bff7-4d20-b618-e69a41de2502">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_section_id_b51e3543-f8b5-4d5d-a2aa-a911f4a95b1a">Clinical Studies</a></span>) and in 3.3% of 61 patients treated with placebo for two months. Adverse events occurring in the doxercalciferol group at a frequency of 2% or greater and more frequently than in the placebo group are presented in <span class="Bold">Table 3</span> below:</p>
<a name="_Refid_03eb870a-7af0-4ea5-b54a-3f8cfbfc5"></a><table>
<caption><span>Table 3: Adverse Events Reported by ≥2% of Doxercalciferol Treated Patients and More Frequently Than Placebo During the Double-Blind Phase of Two Clinical Studies</span></caption>
<col width="44%">
<col width="33%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Doxercalciferol (N=61) %</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Placebo (N=61) %</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Body as a Whole</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Cardiovascular System</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Digestive System</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Musculoskeletal System</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Metabolic and Nutritional</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">34.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increase</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Nervous System</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep Disorder</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Respiratory System</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Skin</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> Pruritis</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.6</p></td>
</tr>
</tbody>
</table>
<p>A patient who reported the same medical term more than once was counted only once for that medical term.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc230597-00df-4a73-b8de-4f66e3310584"></a><a name="section-8.2"></a><p></p>
<h2>Pre-Dialysis</h2>
<p class="First">Doxercalciferol has been evaluated for safety in clinical studies in 55 patients (27 active and 28 placebo) with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>, Stages 3 or 4. In two placebo-controlled, double-blind, multicenter studies, discontinuation of therapy due to any adverse event occurred in one (3.7%) of 27 patients treated with doxercalciferol for 24 weeks (dosage titrated to achieve target iPTH levels, see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_71f42e37-bff7-4d20-b618-e69a41de2502">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_section_id_b51e3543-f8b5-4d5d-a2aa-a911f4a95b1a">Clinical Studies</a></span>) and in three (10.7%) of 28 patients treated with placebo for 24 weeks. Adverse events occurring in the doxercalciferol group at a frequency of 5% or greater and more frequently than in the placebo group are as follows: <span class="Bold">Body as a Whole </span>– <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>; <span class="Bold">Digestive System </span>– <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>; <span class="Bold">Hematologic and Lymphatic </span>– <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>; <span class="Bold">Metabolic and Nutritional </span>– <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>; <span class="Bold">Nervous System </span>– <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>; <span class="Bold">Respiratory System </span>– <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>. </p>
<p>Potential adverse effects of doxercalciferol are, in general, similar to those encountered with excessive vitamin D intake. The early and late signs and symptoms of vitamin D <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> associated with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> include:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6a5e460-6804-4d3f-8a61-821e7779e057"></a><a name="section-8.2.1"></a><p></p>
<h3>Early</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, metallic taste, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_787626bf-a47a-4b50-9a00-a721e2c9d027"></a><a name="section-8.2.2"></a><p></p>
<h3>Late</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (calcific), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, decreased libido, elevated blood urea nitrogen (BUN), <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, elevated serum aspartate transaminase (AST) and alanine transaminase (ALT), ectopic calcification, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, arrested growth, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, and, rarely, overt <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_885ace47-c251-4023-83b0-55747d2ffd2b"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Administration of doxercalciferol to patients in excess doses can cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and oversuppression of PTH secretion leading in certain cases to <span class="product-label-link" type="condition" conceptid="4126449" conceptname="Adynamic bone disease">adynamic bone disease</span>. High intake of calcium and phosphate concomitant with doxercalciferol may lead to similar abnormalities. High levels of calcium in the dialysate bath may contribute to <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a91205ac-fbda-4675-ba13-5d8ae3b75bd6"></a><a name="section-9.1"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> and Overdosage</h2>
<p class="First">General treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (greater than 1 mg/dL above the upper limit of the normal range in dialysis patients; &gt;10.7 mg/dL in pre-dialysis patients) consists of immediate suspension of doxercalciferol therapy, institution of a low calcium diet, and withdrawal of calcium supplements. Serum calcium levels should be determined at least weekly until normocalcemia ensues. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> usually resolves in 2 to 7 days. When serum calcium levels have returned to within normal limits, doxercalciferol therapy may be reinstituted at a dose that is lower (at least 2.5 mcg in dialysis patients and 0.5 mcg in pre-dialysis patients) than prior therapy. In dialysis patients, serum calcium levels should be obtained weekly after all dosage changes and during subsequent dosage titration. Persistent or markedly elevated serum calcium levels may be corrected by dialysis against a reduced calcium or calcium-free dialysate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ee5e8f6-1fe3-4272-a9d5-3a7011f26a8e"></a><a name="section-9.2"></a><p></p>
<h2>Treatment of Accidental Overdosage of Doxercalciferol</h2>
<p class="First">The treatment of acute accidental overdosage of doxercalciferol should consist of general supportive measures. If drug ingestion is discovered within a relatively short time (10 minutes), induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage may be of benefit in preventing further absorption. If drug ingestion is discovered later than 10 minutes post-ingestion, the administration of mineral oil may promote its fecal elimination. Serial serum electrolyte determinations (especially calcium), rate of urinary calcium excretion, and assessment of electrocardiographic abnormalities due to <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> should be obtained. Such monitoring is critical in patients receiving digitalis. Discontinuation of supplemental calcium and institution of a low calcium diet are also indicated in accidental overdosage. If persistent and markedly elevated serum calcium levels occur, treatment with standard medical care should be followed, as needed. Based on similarities between doxercalciferol and its active metabolite, 1α,25-(OH)<span class="Sub">2</span>D<span class="Sub">2</span>, it is expected that doxercalciferol is not removed from the blood by dialysis. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1ede2c7f-0d1a-46ed-8348-2105dd3df30a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_606b3091-c9af-472e-ab44-810d83eadc98"></a><a name="section-10.1"></a><p></p>
<h2>Adult Administration</h2>
<p class="First">The optimal dose of Doxercalciferol Capsules must be carefully determined for each patient. <span class="Bold">Table 4</span> provides the current recommended therapeutic target levels for iPTH in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>:</p>
<a name="_Refid_7adf1684-e7fc-4079-9ea5-ea9f5e32e"></a><table>
<caption><span>Table 4: Target Range of Intact Plasma PTH by Stage of CKD</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule" align="center"><p class="First"><span class="Bold">CKD Stage</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">GFR (mL/min/1.73 m<span class="Sup">2</span>)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Target "intact" PTH (pg/mL)</span></p></td>
</tr>
<tr>
<td class="Toprule" align="center"><p class="First">3</p></td>
<td class="Toprule" align="center"><p class="First">30 to 59</p></td>
<td class="Toprule" align="center"><p class="First">35 to 70</p></td>
</tr>
<tr>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">15 to 29</p></td>
<td align="center"><p class="First">70 to 110</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule" align="center"><p class="First">5</p></td>
<td class="Botrule" align="center"><p class="First">&lt;15 (or dialysis)</p></td>
<td class="Botrule" align="center"><p class="First">150 to 300</p></td>
</tr>
</tbody>
</table>
<p>From Table 15 of National Kidney Foundation. <span class="Italics">K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span>. </span>Am J Kidney Dis 42:S1-S202, 2003 (suppl 3)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a4fe4d0-b4e7-4943-969f-626fc3ae456b"></a><a name="section-10.1.1"></a><p></p>
<h3>Dialysis</h3>
<p class="First">The recommended initial dose of Doxercalciferol Capsules is 10 mcg administered three times weekly at dialysis (approximately every other day). The initial dose should be adjusted, as needed, in order to lower blood iPTH into the range of 150 to 300 pg/mL. The dose may be increased at 8-week intervals by 2.5 mcg if iPTH is not lowered by 50% and fails to reach the target range. The maximum recommended dose of doxercalciferol is 20 mcg administered three times a week at dialysis for a total of 60 mcg per week. Drug administration should be suspended if iPTH <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100 pg/mL and restarted one week later at a dose that is at least 2.5 mcg lower than the last administered dose. During titration, iPTH, serum calcium, and serum phosphorus levels should be obtained weekly. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, or a serum calcium times serum phosphorus product greater than 55 mg<span class="Sup">2</span>/dL<span class="Sup">2</span> is noted, the dose of Doxercalciferol Capsules should be decreased or suspended and/or the dose of phosphate binders should be appropriately adjusted. If suspended, the drug should be restarted at a dose that is at least 2.5 mcg lower.</p>
<p>Dosing must be individualized and based on iPTH levels with monitoring of serum calcium and serum phosphorus levels. The following is a suggested approach in dose titration:</p>
<a name="_Refid_96e52358-211f-46c0-8302-8074d3d11"></a><table>
<caption><span>Table 5: Dialysis Dosing Recommendations</span></caption>
<col width="21%">
<col width="79%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Initial Dosing</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Underline">iPTH Level</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Underline">Doxercalciferol Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&gt;400 pg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10 mcg three times per week at dialysis</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Dose Titration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Underline">iPTH Level</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Underline">Doxercalciferol Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above 300 pg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increase by 2.5 mcg at eight-week intervals as necessary</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">150 to 300 pg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Maintain</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;100 pg/mL</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Suspend for one week, then resume at a dose that is at least 2.5 mcg lower</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c24790b-f7c9-436c-8611-265832e997c6"></a><a name="section-10.1.2"></a><p></p>
<h3>Pre-Dialysis</h3>
<p class="First">The recommended initial dose of Doxercalciferol Capsules is 1 mcg administered once daily. The initial dose should be adjusted, as needed, in order to lower blood iPTH to within target ranges (see table below). The dose may be increased at 2-week intervals by 0.5 mcg to achieve the target range of iPTH. The maximum recommended dose of Doxercalciferol Capsules is 3.5 mcg administered once per day.</p>
<p>Serum levels of calcium and phosphorus and plasma levels of iPTH should be monitored at least every two weeks for 3 months after initiation of Doxercalciferol Capsules therapy or following dose adjustments in Doxercalciferol Capsules therapy, then monthly for 3 months, and every 3 months thereafter. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, or a serum calcium times phosphorus product greater than 55 mg<span class="Sup">2</span>/dL<span class="Sup">2</span> is noted, the dose of Doxercalciferol Capsules should be decreased or suspended and/or the dose of phosphate binders should be appropriately adjusted. If suspended, the drug should be restarted at a dose that is at least 0.5 mcg lower.</p>
<p>Dosing must be individualized and based on iPTH levels with monitoring of serum calcium and serum phosphorus levels. <span class="Bold">Table 6</span> presents a suggested approach in dose titration:</p>
<a name="_Refid_4a3615ba-2ca1-4723-9024-333c8889b"></a><table>
<caption><span>Table 6: Pre-Dialysis Dosing Recommendations </span></caption>
<col width="32%">
<col width="68%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Initial Dosing</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Underline">iPTH Level</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Underline">Doxercalciferol Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&gt;70 pg/mL (Stage 3)</p></td>
<td class="Rrule"><p class="First">1 mcg once per day</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&gt;110 pg/mL (Stage 4)</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Dose Titration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Underline">iPTH Level</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Underline">Doxercalciferol Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Above 70 pg/mL (Stage 3)</p></td>
<td class="Rrule"><p class="First">Increase by 0.5 mcg at two-week intervals as necessary</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">110 pg/mL (Stage 4)</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">35 to 70 pg/mL (Stage 3)</p></td>
<td class="Rrule"><p class="First">Maintain</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">70 to 110 pg/mL (Stage 4)</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&lt;35 pg/mL (Stage 3)</p></td>
<td class="Rrule"><p class="First">Suspend for one week, then resume at a dose that is at least 0.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">&lt;70 pg/mL (Stage 4)</p></td>
<td class="Botrule Rrule"><p class="First">mcg lower</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3b747d4a-64ca-485a-8378-13909fe79122"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Doxercalciferol Capsules are supplied as a clear, oily solution encapsulated in oval shaped, soft gelatin capsules. The 0.5 mcg capsules are orange, opaque with "r" imprinted in black ink along one side of the capsule. The 1 mcg capsules are light peach, opaque with "r" imprinted in black ink along one side of the capsule. The 2.5 mcg capsules are yellow, opaque with "r" imprinted in black ink along one side of the capsule. </p>
<p>0054-0338-19      0.5 mcg, orange capsules, bottle of 50</p>
<p>0054-0388-19	  1 mcg, light peach capsules, bottle of 50</p>
<p>0054-0339-19      2.5 mcg, yellow capsules, bottle of 50</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2105748-19c1-43cd-ad0e-e1359bdd755a"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.]</p>
<p>Made in India.</p>
<p>Manufactured by:</p>
<p>Cipla Limited, Kurkumbh, Maharashtra, India</p>
<p>Manufactured for:</p>
<p>Roxane Laboratories, Inc., Columbus, Ohio 43216</p>
<p> <span class="Bold">DD50A Revised September 2013</span></p>
<p> © RLI, 2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1d609f75-a071-403e-9c75-6df5bb568596"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Doxercalciferol Capsules, 0.5 mcg</p>
<p>Roxane Laboratories, Inc.</p>
<p>NDC 0054-0338-19</p>
<div class="Figure">
<a name="id1295"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Doxercalciferol Capsules SPL\Labels\DC89 A Doxercalciferol Cap 0.5mcg.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed&amp;name=1bb3ce2f-c77a-436f-980f-a02668f99fed-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ce32c0db-ec96-4794-9987-485c45e0260a"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL </h1>
<p class="First">Doxercalciferol Capsules, 1 mcg</p>
<p>Roxane Laboratories, Inc.</p>
<p>NDC 0054-0388-19</p>
<div class="Figure">
<a name="id1312"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Doxercalciferol Capsules SPL\Labels\GN01 A Doxercalciferol Cap 1mcg.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed&amp;name=1bb3ce2f-c77a-436f-980f-a02668f99fed-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7dad02b3-71dc-4836-8a94-d5e46766570a"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Doxercalciferol Capsules, 2.5 mcg</p>
<p>Roxane Laboratories, Inc.</p>
<p>NDC 0054-0339-19</p>
<div class="Figure">
<a name="id-1957637508"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Doxercalciferol Capsules SPL\Labels\DC90 A Doxercalciferol Cap 2.5mcg.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed&amp;name=1bb3ce2f-c77a-436f-980f-a02668f99fed-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXERCALCIFEROL 		
					</strong><br><span class="contentTableReg">doxercalciferol capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0338</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXERCALCIFEROL</strong> (DOXERCALCIFEROL) </td>
<td class="formItem">DOXERCALCIFEROL</td>
<td class="formItem">0.5 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">r</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0338-19</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091433</td>
<td class="formItem">02/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXERCALCIFEROL 		
					</strong><br><span class="contentTableReg">doxercalciferol capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0388</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXERCALCIFEROL</strong> (DOXERCALCIFEROL) </td>
<td class="formItem">DOXERCALCIFEROL</td>
<td class="formItem">1 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">r</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0388-19</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091433</td>
<td class="formItem">02/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXERCALCIFEROL 		
					</strong><br><span class="contentTableReg">doxercalciferol capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0339</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXERCALCIFEROL</strong> (DOXERCALCIFEROL) </td>
<td class="formItem">DOXERCALCIFEROL</td>
<td class="formItem">2.5 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">r</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0339-19</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091433</td>
<td class="formItem">02/18/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roxane Laboratories, Inc.
							(833490464)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Roxane Laboratories, Inc. (833490464)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cipla</td>
<td class="formItem"></td>
<td class="formItem">917066446</td>
<td class="formItem">MANUFACTURE(0054-0388, 0054-0338, 0054-0339)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Polymed Therapeutics, Inc.</td>
<td class="formItem"></td>
<td class="formItem">528197487</td>
<td class="formItem">API MANUFACTURE(0054-0388, 0054-0338, 0054-0339)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1bb3ce2f-c77a-436f-980f-a02668f99fed</div>
<div>Set id: 1bb3ce2f-c77a-436f-980f-a02668f99fed</div>
<div>Version: 1</div>
<div>Effective Time: 20140218</div>
</div>
</div> <div class="DistributorName">Roxane Laboratories, Inc.</div></p>
</body></html>
